Latest Manufacturing Partnerships News

Firebird Metals is moving from manganese exploration towards downstream battery materials, with its Perth demonstration plant backed by a A$2 million ARENA grant. But the ASX-listed company remains loss-making, has A$3.61 million in cash and faces a material uncertainty over its ability to continue without further funding.

Biome Australia Limited (ASX:BIO) delivered its second consecutive profitable year in FY26, with revenue rising 30% to $23.9 million and operating cash flow turning positive. But the headline $3.6 million profit includes a $2.4 million deferred tax benefit, leaving FY27 execution as the real test of the company’s growth plan.

OMG Group has raised $1.5 million through a placement featuring a $350,000 strategic investment from Slades Beverages, which will become its oat milk manufacturing partner. The company plans a $250,000 Share Purchase Plan and director participation to fuel product launches and supply expansion following a 48% revenue surge in FY26.

Provaris Energy has teamed up with Himile Heavy Industries to transition its hydrogen tank production from prototype to commercial scale, leveraging Himile's industrial manufacturing expertise and facilities in China.

Cambium Bio has secured FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development costs and timelines. Despite a AUD 4.1 million loss for FY2026, the company strengthened its funding position and manufacturing partnerships ahead of patient dosing targeted for late 2026.

Epiminder Limited reported a $42.7 million loss for FY26, driven by clinical trial and product development costs following a $125 million IPO. The company progresses its FDA-approved Minder implantable EEG monitor with a pivotal US trial and next-gen device on track for 2028 launch.

Entropy Neurodynamics has partnered with BioCina to establish GMP manufacturing for its intravenous psilocin formulation TRP-8803, a critical step toward late-stage clinical trials and commercialisation.

Radiopharm Theranostics is gearing up for a pivotal Phase 3 trial of its brain metastases imaging agent RAD101, following strong Phase 2b results and an upcoming FDA meeting to finalise trial design.

The Calmer Co. has locked in an exclusive global distribution agreement for its kava extract ingredients, underpinning a potential A$25 million revenue stream over three years across key markets including the US and ASEAN.

The Calmer Co. has pushed back the closing date of its $3.5 million renounceable entitlement offer to give shareholders more time to participate, including those overseas.

The Calmer Co. has signed a binding heads of agreement with Kaiming Agro Processing to establish a long-term manufacturing partnership, leveraging advanced extraction technology in Fiji to scale its premium botanical ingredients business globally.

Cleo Diagnostics has entered the critical Analytical Validation phase for its ovarian cancer blood test, progressing toward an FDA 510(k) submission targeted for the first half of 2027. The company also secured a U.S. reimbursement pathway to support early market entry post-clearance, backed by a cash balance of A$6.2 million.